Literature DB >> 22149452

Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans.

Solveig K Matthesen1, Thomas Larsen, Henrik Vase, Thomas G Lauridsen, Erling B Pedersen.   

Abstract

BACKGROUND: Potassium is the main intracellular cation, which contributes to keeping the intracellular membrane potential slightly negative and elicits contraction of smooth, skeletal and cardiac muscle. A change in potassium intake modifies both cardiovascular and renal tubular function. The purpose of the trial was to investigate the effect of dietary potassium supplementation, 100 mmol daily in a randomized, placebo-controlled, crossover trial of healthy participants during two periods of 28 days duration. The participants (N = 21) received a diet that was standardized regarding energy requirement, and sodium and water intake.
METHODS: 24-hour ambulatory blood pressure (ABP) and applanation tonometry were used to assess blood pressure, pulse wave velocity (PWV), augmentation index (AIx) and central blood pressure (CBP). Immunoassays were used for measurements of plasma concentrations of vasoactive hormones: renin (PRC), angiotensin II (Ang II), aldosterone (Aldo), atrial natriuretic peptide (ANP), vasopressin (AVP), pro-brain natriuretic peptide (pro-BNP),endothelin (Endo), urinary excretions of aquaporin 2 (AQP2), cyclic AMP (cAMP), and the β-fraction of the epithelial sodium channel (ENaC(ß)).
RESULTS: AQP2 excretion increased during potassium supplementation, and free water clearance fell. The changes in urinary potassium excretion and urinary AQP2 excretion were significantly and positively correlated. Aldo increased. GFR, u-ENaC- β, PRC, Ang II, ANP, BNP, Endo, blood pressure and AI were not significantly changed by potassium supplementation, whereas PWV increased slightly.
CONCLUSIONS: Potassium supplementation changed renal tubular function and increased water absorption in the distal part of the nephron. In spite of an increase in aldosterone in plasma, blood pressure remained unchanged after potassium supplementation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22149452     DOI: 10.3109/00365513.2011.635216

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  16 in total

Review 1.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

2.  Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  World J Nephrol       Date:  2015-07-06

3.  Effects of sodium and potassium supplementation on blood pressure and arterial stiffness: a fully controlled dietary intervention study.

Authors:  L Gijsbers; J I Dower; M Mensink; E Siebelink; S J L Bakker; J M Geleijnse
Journal:  J Hum Hypertens       Date:  2015-02-12       Impact factor: 3.012

4.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

5.  Dietary approaches to prevent hypertension.

Authors:  Lydia A Bazzano; Torrance Green; Teresa N Harrison; Kristi Reynolds
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

6.  Central Blood Pressure Responses to Dietary Sodium and Potassium Interventions.

Authors:  Xiaolong Xing; Fangchao Liu; Xueli Yang; Chen Huang; Dingding Zhang; Shufeng Chen; Jichun Chen; Jianxin Li; Zhendong Liu; Fanghong Lu; Dongfeng Gu; Jianfeng Huang
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

7.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 8.  Use of Urine Biomarkers to Assess Sodium Intake: Challenges and Opportunities.

Authors:  Mary E Cogswell; Joyce Maalouf; Paul Elliott; Catherine M Loria; Sheena Patel; Barbara A Bowman
Journal:  Annu Rev Nutr       Date:  2015-05-06       Impact factor: 11.848

9.  Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial.

Authors:  Frank H Mose; Henrik Vase; Thomas Larsen; Anne S P Kancir; Renata Kosierkiewic; Bartlomiej Jonczy; Annebirthe B Hansen; Anna E Oczachowska-Kulik; Ingrid M Thomsen; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2014-03-24       Impact factor: 2.388

10.  Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.

Authors:  Safa Al Therwani; Frank Holden Mose; Janni Majgaard Jensen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2014-06-25       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.